Lack of effect of mood stabilizers or neuroleptics on GSK-3β protein levels and GSK-3 activity

International Journal of Neuropsychopharmacology

Volumn 6, Issue 2, 2003, Pages 117-120

  Kozlovsky, Nitsan ^a   Nadri, Carmit ^a   Belmaker, Robert H ^a   Agam, Galila ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b MENTAL HEALTH CENTER   (Israel)

Author keywords

Animal model; Frontal cortex; GSK 3 ; Mood stabilizers; Neuroleptics

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; HALOPERIDOL; LITHIUM CHLORIDE; NEUROLEPTIC AGENT; VALPROIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CADAVER; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; MENTAL PATIENT; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

AFFECT; ANIMALS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BLOTTING, WESTERN; CHLORPROMAZINE; CLOZAPINE; FRONTAL LOBE; GLYCOGEN SYNTHASE KINASE 3; HALOPERIDOL; LITHIUM; RATS; RATS, SPRAGUE-DAWLEY; VALPROIC ACID;

EID: 0038164860     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145703003353     Document Type: Article

References (22)

1. Chen G, Huang LD, Jiang YM, Manji HK (1999). The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. Journal of Neurochemistry 72, 1327-1330.
2. Chen RH, Ding WV, McCormick F (2000). Wnt signalling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C. Journal of Biological Chemistry 275, 17894-17899.
3. Duncan GE, Zorn S, Lieberman JA (1999). Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Molecular Psychiatry 4, 418-428.
4. Ebstein RP, Hermoni M, Belmaker RH (1980). The effect of lithium on noradrenaline-induced cyclic AMP accumulation in rat brain: inhibition after chronic treatment and absence of supersensitivity. Journal of Pharmacology and Experimental Therapeutics 213, 161-167.
5. Grimes CA, Jope RS (2001). The multifaceted roles of glycogen synthase kinase 3beta in cellular signalling. Progress in Neurobiology 65, 391-426.
6. Haeusler G (1990). Pharmacology of beta-blockers: classical aspects and recent developments. Journal of Cardiovascular Pharmacology 16, S1-S9.
7. Jope RS (1999). Anti-bipolar therapy: mechanism of action of lithium. Molecular Psychiatry 4, 117-128.
8. Klein PS, Melton DA (1996). A molecular mechanism for the effect of lithium on development. Proceedings of the National Academy of Sciences USA 93, 8455-8459.
9. Kozlovsky N, Belmaker RH, Agam G (2000). Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. American Journal of Psychiatry 157, 831-833.
10. Kozlovsky N, Belmaker RH, Agam G (2001). Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophrenia Research 52, 101-105.
11. Kumer SC, Vrana KE (1996). Intricate regulation of tyrosine hydroxylase activity and gene expression. Journal of Neurochemistry 67, 443-462.
12. Lau KF, Miller CC, Anderton BH, Shaw PC (1999). Molecular cloning and characterization of the human glycogen s)mthase kinase-3beta promoter. Genomics 60, 121-128.
13. Lesort M, Greendorfer A, Stockmeier C, Johnson GV, Jope RS (1999). Glycogen synthase kinase-3beta, beta-catenin, and tau in postmortem bipolar brain. Journal of Neural Transmission 106, 1217-1222.
14. Li M, Wang X, Meintzer MK, Laessig T, Birnbaum MJ, Heidenreich KA (2000). Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta. Molecular Cell Biology 20, 9356-9363.
15. Manji HK (2001). Glycogen synthase kinase 3beta (GSK-3beta): a therapeutically relevant biochemical target for bipolar disorders? The World Journal of Biological Psychiatry 2 (Suppl. 1), Abst. S014-02.
16. Murphy DL, Belmaker RH, Wyatt RJ (1975). Monoamine oxidase in schizophrenia and other behavioural disorders. In: Kety SS, Matthysse S (Eds.), Catecholamines and their Enzymes in Relation to Neuropathology of Schizophrenia (pp. 221-248). New York: Pergamon Press.
17. Piomelli D, Di Marzo V (1993). Dopamine D2 receptor signalling via the arachidonic acid cascade: modulation by cAMP-dependent protein kinase A and prostaglandin E2. Journal of Lipid Mediators 6, 433-443.
18. Ridley DL, Rogers A, Wonnacott S (2001). Differential effects of chronic drug treatment on alpha3* and alpha7 nicotinic receptor binding sites, in hippocampal neurones and SH-SY5Y cells. British Journal of Pharmacology 133, 1286-1295.
19. Ryves WJ, Fryer L, Dale T, Harwood AJ (1998). An assay for glycogen synthase kinase 3 (GSK-3) for use in crude cell extracts. Analytical Biochemistry 264, 124-127.
20. Ryves WJ, Harwood AJ, Fryer L, Dale T (2001). Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. An assay for glycogen synthase kinase 3 (GSK-3) for use in crude cell extracts. Biochemical and Biophysical Research Communications 280, 720-725.
21. Shaldubina A, Einat H, Szechtman H, Shimon H, Belmaker RH (2002). Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. Journal of Neural Transmission 109, 433-440.
22. Stambolic V, Ruel L, Woodgett JR (1996). Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Current Biology 6, 1664-1668.